Breaking News Instant updates and real-time market news.

PFE

Pfizer

$37.43

0.26 (0.70%)

19:16
07/10/18
07/10
19:16
07/10/18
19:16

Pfizer to roll back July 1 price hikes after speaking with Trump

In a statement provided to CNBC's Meg Tirrell, Pfizer said it will roll back its July 1 price increases "to give the president an opportunity to work on his blueprint to strengthen the healthcare system and provide more access for patients." The company released the statement following an "extensive discussion" with President Trump. Pfizer said it will return such prices to their pre-July 1 levels as soon as technically possible, and the prices will remain in effect until the earlier of when the president's blueprint goes into effect or the end of the year. In addition, the drug giant said that the price declines the company took as of July 1 will remain in effect. Reference Link

  • 22

    Aug

  • 10

    Sep

PFE Pfizer
$37.43

0.26 (0.70%)

06/08/18
06/08/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Pfizer (PFE) and Eli Lilly (LLY) were initiated with an Overweight at Cantor Fitzgerald. 2. LivaNova (LIVN) initiated with a Buy at Stifel. 3. Occidental Petroleum (OXY) and Chevron (CVX) were initiated with a Buy at Mizuho while ConocoPhillips (COP) and Exxon Mobil (XOM) were initiated with a Neutral. 4. LeMaitre (LMAT) resumed with a Buy at Roth Capital. 5. Savara (SVRA) initiated with an Outperform, sees 300% upside, says Evercore ISI. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
06/13/18
MSCO
06/13/18
NO CHANGE
MSCO
HHS 'smoke signals' worth noting for drugmakers, says Morgan Stanley
After HHS Secretary Alex Azar spoke at a two-hour Senate hearing, Morgan Stanley analyst David Risinger noted that Azar suggested that U.S. drug pricing needs to move to a system without rebates and said payments from drugmakers to PBMs should be eliminated. In listing four HHS actions that could hurt manufacturers, Risinger pointed out that Azar said he is interested in removing 100% cap on Medicaid rebates; he would like to adjust the Part D protected drug classes so that plans can extract rebates from manufacturers; HHS wants to require manufacturers to disclose drug list prices in TV ads; and HHS is focused on transitioning Part B to lower-priced private sector management. In summary, the analyst said that for drugmakers there was "no fire, but smoke signals worth noting." Publicly traded large-cap drugmakers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
06/19/18
MSCO
06/19/18
NO CHANGE
Target $43
MSCO
Overweight
Pfizer doesn't appear focused on large-scale M&A, says Morgan Stanley
After meeting with Pfizer's head of IR, Chuck Triano, Morgan Stanley analyst David Risinger said his key takeaway was that the company sees the potential for "mid single digit plus" sales growth starting early next decade. Given that Lyrica is the only major patent expiration Pfizer will face over the next several years and that it has upcoming organic growth drivers, management seems focused on bolt-on acquisitions in existing therapeutic areas and large-scale M&A does not appear to be a focus, Risinger added. He keeps an Overweight rating and $43 price target on Pfizer shares.
06/28/18
WELS
06/28/18
NO CHANGE
WELS
Wells says Amazon deal, Walgreens results have negative read for drug pricing
After Amazon (AMZN) agreed to acquire online pharmacy PillPack, reportedly for $1B, Wells Fargo analyst David Maris noted that he has long stated that Amazon would enter the pharmacy business and warned about the risk to drug pricing in such a scenario. Maris also noted that Walgreens (WBA) reported its U.S. retail pharmacy comparable store sales fell 1.2% in Q3, adding that retailers tend to push drugmakers on price when they feel pressure and the read-through from its report may be negative for drug pricing. Publicly traded large-cap drugmakers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).

TODAY'S FREE FLY STORIES

BLMN

Bloomin' Brands

$19.57

-0.11 (-0.56%)

08:03
10/22/18
10/22
08:03
10/22/18
08:03
Hot Stocks
Barington calls on Bloomin' directors to improve board oversight of management »

Barington Capital Group,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

KLXE

KLX Energy

$32.22

0.27 (0.85%)

08:02
10/22/18
10/22
08:02
10/22/18
08:02
Conference/Events
KLX Energy to host conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

MCD

McDonald's

$167.45

0.61 (0.37%)

08:02
10/22/18
10/22
08:02
10/22/18
08:02
Recommendations
McDonald's analyst commentary  »

McDonald's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

HON

Honeywell

$153.49

-1.73 (-1.11%)

08:02
10/22/18
10/22
08:02
10/22/18
08:02
Recommendations
Honeywell analyst commentary  »

Honeywell growth and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AROW

Arrow Financial

$34.92

-0.39 (-1.10%)

08:01
10/22/18
10/22
08:01
10/22/18
08:01
Earnings
Arrow Financial reports Q3 EPS 64c, one estimate 65c »

Reports Q3 loan loss…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ACN

Accenture

$158.35

2.15 (1.38%)

08:01
10/22/18
10/22
08:01
10/22/18
08:01
Hot Stocks
Accenture agrees to acquire New Content, terms not disclosed »

Accenture has entered…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 28

    Oct

  • 13

    Nov

MCRB

Seres Therapeutics

08:01
10/22/18
10/22
08:01
10/22/18
08:01
Initiation
Seres Therapeutics initiated  »

Seres Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLF

Cleveland-Cliffs

$11.05

-0.425 (-3.71%)

08:00
10/22/18
10/22
08:00
10/22/18
08:00
Recommendations
Cleveland-Cliffs analyst commentary  »

Cleveland-Cliffs dividend…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VFC

VF Corp.

$77.74

-9.33 (-10.72%)

08:00
10/22/18
10/22
08:00
10/22/18
08:00
Recommendations
VF Corp. analyst commentary  »

VF Corp. near-term…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DVAX

Dynavax

$10.90

-0.47 (-4.13%)

08:00
10/22/18
10/22
08:00
10/22/18
08:00
Recommendations
Dynavax analyst commentary  »

Dynavax price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

LII

Lennox

$192.83

-3.91 (-1.99%)

08:00
10/22/18
10/22
08:00
10/22/18
08:00
Earnings
Lennox reports Q3 adjusted EPS $2.72, consensus $2.92 »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

YNDX

Yandex

$27.42

-2.07 (-7.02%)

08:00
10/22/18
10/22
08:00
10/22/18
08:00
Options
Yandex put buyer realizes 65% same-day gains »

Notable profits for the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

ENIA

Enel Americas

$7.73

0.01 (0.13%)

07:59
10/22/18
10/22
07:59
10/22/18
07:59
Initiation
Enel Americas initiated  »

Morgan Stanley resumes…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UNFI

United Natural Foods

$26.78

-0.16 (-0.59%)

, SVU

Supervalu

$32.50

0.01 (0.03%)

07:57
10/22/18
10/22
07:57
10/22/18
07:57
Recommendations
United Natural Foods, Supervalu analyst commentary  »

United Natural Foods…

UNFI

United Natural Foods

$26.78

-0.16 (-0.59%)

SVU

Supervalu

$32.50

0.01 (0.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Oct

SU

Suncor

$35.73

0.24 (0.68%)

07:55
10/22/18
10/22
07:55
10/22/18
07:55
Upgrade
Suncor rating change  »

Suncor upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

  • 07

    Nov

VIOT

Viomi Technology

$8.11

-0.21 (-2.52%)

07:55
10/22/18
10/22
07:55
10/22/18
07:55
Initiation
Viomi Technology initiated  »

Viomi Technology…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GLD

SPDR Gold Trust

$116.01

0.11 (0.09%)

07:55
10/22/18
10/22
07:55
10/22/18
07:55
Technical Analysis
SPDR Gold Trust: Pivot points, pivot low broken »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MRTX

Mirati Therapeutics

$40.04

-1.82 (-4.35%)

07:55
10/22/18
10/22
07:55
10/22/18
07:55
Hot Stocks
Mirati Therapeutics provides sitravatinib update after meeting with FDA »

Mirati Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

JTPY

JetPay

$2.07

(0.00%)

07:55
10/22/18
10/22
07:55
10/22/18
07:55
Hot Stocks
Breaking Hot Stocks news story on JetPay »

JetPay trading halted,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EPZM

Epizyme

$8.76

-0.04 (-0.45%)

07:55
10/22/18
10/22
07:55
10/22/18
07:55
Conference/Events
Epizyme to hold a conference call »

Management discusses the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

FCAU

Fiat Chrysler

$15.52

0.035 (0.23%)

07:54
10/22/18
10/22
07:54
10/22/18
07:54
Recommendations
Fiat Chrysler analyst commentary  »

Fiat Chrysler sale of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

EWZ

MSCI Brazil Index

$38.92

0.31 (0.80%)

07:54
10/22/18
10/22
07:54
10/22/18
07:54
Technical Analysis
MSCI Brazil Index: Pivot points, pivot high broken »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CJREF

Corus Entertainment

$0.00

(0.00%)

07:53
10/22/18
10/22
07:53
10/22/18
07:53
Upgrade
Corus Entertainment rating change  »

Corus Entertainment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LTHM

Livent

$16.35

(0.00%)

07:53
10/22/18
10/22
07:53
10/22/18
07:53
Initiation
Livent initiated  »

Livent initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ACRX

AcelRx

$3.62

-0.53 (-12.77%)

07:52
10/22/18
10/22
07:52
10/22/18
07:52
Recommendations
AcelRx analyst commentary  »

AcelRx price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.